Keywords: -celtrix, pharmaceuticals, somatokine, shows, potential, antidiabetic, celtrix
-Celtrix Pharmaceuticals' SomatoKine shows potential as an antidiabetic
Article | 04 March 1999
- Celtrix Pharmaceuticals' SomatoKine (IGF-1/BP3) decreased the meandaily insulin requirement by 49% and the average daily blood glucose level by 23% compared ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
